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THE CEO THE CSO
1. THE MONEY
2. THE BUSINESS PLAN  - BUSINESS MILESTONES
3. THE SCIENCE – TECHNICAL MILESTONES
4. ALIGNMENT – CLEAR MODEL OF TECHNOLOGY TRANSFER

























Retos Colaboración – Spain (200K)
Enisa-Spain (200K)
CDTI –Spain (200K)
GRANTS TO THE COMPANY
Delayed CASH (1.5 years)
Non-refundable
ERDF funds – Spain (0.5-1.0M)
EIC Accelerator (SME Instrument)-EU (>2M)
Specialized accelerator programs (>2M)
GRANTS TO THE PUBLIC GROUP
Need a good transfer model!
public money
Before beginning, become an expert in your sources of MONEY
no banks available
STAGE 2: PRECLINICAL
STAGE 3: PHASE I
STAGE 4: PHASE 2






STAGE 1: PROOF OF CONCEPT






















STAGE 3: PHASE I
STAGE 4: PHASE 2
STAGE 5: PHASE 3
MARKET AUTHORIZATION
71%





























A case of success
It’s all about MONEY
In order to reach my 1st important business milestone, I need to borrow money: 
when? who? how much? how will I success?
 The more I increase valuation of the Company with founders’ money, the better
 If I want to ask for 8M and give 40%, then I have to convince investors that the 
company’s value is 8M/0,4= 20M
 If I have access to a grant covering 4M, then the value is 4M/0,4= 10M
when? High valuation; when you need it!!
who? Specialized investor (understand the business, connection with licensors, good track record)
how much? The money that you really need to reach a key business milestone
how will I success? TEAM; BUSINESS PLAN; PAST (results translated into business; KoL’s support); 
CONFIDENCE; TIME (alignment, the deal breaker)
STAGE 2: PRECLINICAL
STAGE 3: PHASE I
STAGE 4: PHASE 2
STAGE 5: PHASE 3
MARKET AUTHORIZATION
71%






































Services/Co-development Agreement with 
Public Institution (ALIGMENT!!)
Scientists/Project Managers
Patent Lawyers (the patents!!)
Regulatory People
CFO & Financial Staff







The Best service 
providers!
Opportunity
Vaccines to prevent antibiotic-resistant infections
70% of R&D expenses covered until key business milestone






Vaccines should come first - The review on antimicrobial resistance chaired by Jim O'Neill, May 2016 
Post-Antibiotic Era
Population at risk 2019: 74 million
Deaths in 2018: 700.000
Cost associated in 2018: 40 billion $
Deaths forecasted for 2050: 10 millones
2 Barriers: technology & market introduction
Who’s killing us?
https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1
Phase 1 Phase 2 Phase 3 Total
Candida 0 1 0 1 0 0.3
Clostridium difficile 0 1 1 2 0 0.9
Escherichia coli 1 1 0 2 0 0.5
Gorup B Streptoccocus 1 1 0 2 0 0.5
Shigella 0 1 0 1 0 0.6
Stapylococcus aureus 1 1 1 3 0 1.1
Streptococcus pneumoniae 1 3 0 4 3 1.1
Mycobacterium tuberculosis 0 2 0 2 1 0.6
Acinetobacter baumannii 0 0 0 0 0 0
Pseudomonas aeruginosa 0 0 0 0 0 0
Klebsiella pneumoniae 0 0 0 0 0 0




Table 1. Vaccines against resistant bacteria. Industry pipeline as of Feb 2018







Dr. Michael J. McConnell
Bacteriologist, CSO
KOL Dr. Jerónimo Pachón
25 years director Infection 
Diseases Unit at Hospital 
Univ. Virgen del Rocío of 
Seville
Dr. Francisco León
Immunologist, pharmaceuticla developer, entrepeneur
Ex-VP Janssen-Johnson & Johnson
Co-founder Celimmune & Provention Bio (NASDAQ)
Team
Dr. Juan José Infante
CEO
12 years private biotechnology 
vaccines valuation





National Microbiology Center of Spain Health Institutes  (ISCIII, Madrid)
Insitute of Biomedicine of Seville (IBiS)
Biodextris (CMO active ingredients; Montreal)
Laboratorios Reig-Jofré (CMO final product; Barcelona)
Overcoming the barriers: our pole and our mattress 
Private international organization with headquarters in the USA
 Phase I completed in 4 years
 Technology validation
 Access to NIH preclinical services; Expert Advisory Board
 EUR 5.2 MILLION GRANT (70% R&D)
 Non refundable
 Non dilutive
Technology validated; Manufacturing validated





IP-protected in Europe, USA, Japan, China, India, and México
KaPaVax: multivalent vaccine
KaPaVax: Multi-Presentation of antigens from Pseudomonas aeruginosa and Klebsiella 













Overcoming the barriers: looking for the target population
36 million people with COPD 
in EU and USA
1/3 (12 million) with advanced 
airflow obstruction (FEV1<50% 
expected value)
Recruitment of those with 
severe acute exacerbations 
requiring mechanical ventilation  
for clinical phases II-III
Primary Target Population
Final message
1. Innovative and validated technology for a public health highly unmet need
2. Project and Plan validated by an international organization with highly qualified
experts in the field in the Advisory Board
3. Substantial non-dilutive grant resulting in highly discounted equity
4. The sponsorship of this organization and current talks with pharmaceutical companies
support the potential exit and ROI of investment
THE CEO THE CSO
1. THE MONEY
2. THE BUSINESS PLAN  - BUSINESS MILESTONES
3. THE SCIENCE – TECHNICAL MILESTONES
4. ALIGNMENT – CLEAR MODEL OF TECHNOLOGY TRANSFER
Are you willing to take the journey?
Scientists
Services/Co-development Agreement with 
Public Institution (ALIGMENT!!)
Scientists/Project Managers
Patent Lawyers (the patents!!)
Regulatory People
CFO & Financial Staff







The Best service 
providers!
